Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04753996 · ClinicalTrials.gov registry record
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
A clinical trial of Cholangiocarcinoma and Primary Sclerosing Cholangitis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT04753996: Recruiting study of Cholangiocarcinoma and Primary Sclerosing Cholangitis, sponsored by Mayo Clinic.
NCT04753996 is a study of Cholangiocarcinoma and Primary Sclerosing Cholangitis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 300 participants, below the 381-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04753996, a study of Cholangiocarcinoma and Primary Sclerosing Cholangitis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
Primary Outcome
Number of participants in study.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2035-01-01 |
What NCT04753996 shows while recruiting
NCT04753996 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 381-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (21% lower).
The record links to 3 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04753996 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04753996 about?
NCT04753996 is a clinical study titled "Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients". The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
What is the current status of trial NCT04753996?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-03-08. Estimated completion is 2035-01-01.
What conditions does trial NCT04753996 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Primary Sclerosing Cholangitis, PSC.
Who is sponsoring clinical trial NCT04753996?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04753996 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04753996's enrollment target sits among peer trials
300 15th of 60 higher than 46 of 60 other Cholangiocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cholangiocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI